Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Gestational Breast Cancer Exhibits Distinct Molecular Signatures and Lower Immune Infiltration

2 hours ago 11

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

Gestational breast cancer, defined as breast malignancy diagnosed throughout pregnancy or within the first year postpartum, constitutes a biologically and molecularly distinct clinical entity compared with breast malignancies arising in non-pregnant women of similar age. According to findings from the GEICAM/2012–03 observational registry published in the Journal of Mammary Gland Biology and Neoplasia, tumors that develop in the context of gestation display heightened biological aggressiveness, distinct gene expression profiles, an altered tumor immune microenvironment, and a notably elevated frequency of germline cancer-predisposing alterations. Researchers compared clinicopathological, genomic, and immunological variables from seventy patients diagnosed with gestational breast cancer across participating Spanish medical institutions against age-matched control populations recruited across several prior clinical studies, revealing multiple clear divergence points that differentiate gestational malignancies from ordinary early-onset breast neoplasms.

Breast cancer diagnosed in relation to childbearing accounts for an estimated six to fifteen percent of all breast cancer cases identified in women between the ages of twenty and forty-four. The overall clinical incidence is estimated to occur in roughly one out of every three thousand to ten thousand gestations, positioning breast carcinoma as the fourth most common malignancy diagnosed during pregnancy, trailing malignant melanoma, cervical cancer, and lymphoma. Although women experiencing gestational breast cancer are frequently older than thirty years, with a reported median age of thirty-five years, clinicians have repeatedly documented that these tumors present with poorer overall outcomes than non-gestational cases. Medical literature has debated whether this diminished prognosis stems primarily from diagnostic delays caused by physiological changes in maternal breast tissue or from aggressive intrinsic tumor biology. Pregnancy exhibits a recognized dual role in mammary carcinogenesis, conferring long-term protection when childbearing occurs early in reproductive life, yet elevating transient risk in the immediate years following delivery.

To investigate the genomic and phenotypic underpinnings of these tumors, the GEICAM/2012–03 multicenter observational registry gathered archival formalin-fixed paraffin-embedded primary tissue specimens from seventy women diagnosed with gestational breast cancer between April 1987 and January 2015. Within this primary analytical group, thirty patients received their initial cancer diagnosis during ongoing pregnancy, while forty patients received their diagnosis during the first twelve months following delivery. To isolate gestational influences from broader age-associated factors, investigators compared these patients against non-gestational cohorts of comparable age, setting forty-two years as the upper age threshold to match the oldest individual within the gestational cohort. Comparator patients were drawn from six distinct Spanish GEICAM research datasets, including the GEICAM/9906 phase three adjuvant chemotherapy trial, the prospective Malaga Cohort, the El Álamo III registry, the LEA metastatic endocrine therapy study, the ConvertHER dynamic biomarker study, and the CIBOMA adjuvant capecitabine trial.

Detailed clinicopathological characterization revealed that tumors arising during or immediately after pregnancy frequently display high-risk biological features. When evaluated alongside age-equivalent non-gestational patients from the GEICAM/9906 trial, the Malaga Cohort, and the El Álamo III project, gestational tumors demonstrated a significantly higher proportion of high histological grades, negative hormone receptor status, and pronounced cellular proliferation. Specifically, ninety percent of gestational breast cancer patients presented with tumor Ki67 labeling indices of twenty percent or greater, compared with substantially lower frequencies in non-gestational controls. Furthermore, sixty-two percent of gestational cases exhibited high Risk of Recurrence scores based on proliferation-related genes within the PAM50 panel, compared to forty-one point four percent in the comparator series. A positive family history of breast or ovarian malignancy among first- or second-degree relatives was also markedly more common among gestational patients, documented in fifty-two percent of cases compared to twenty-seven percent within the El Álamo III control cohort.

Genetic analysis of germline susceptibility genes highlighted a marked enrichment of deleterious alterations among women diagnosed with gestational breast cancer. Germline BRCA1 and BRCA2 mutational status was documented for forty-three patients within the gestational registry. Pathogenic or deleterious mutations were verified in eight individuals, representing eighteen point six percent of tested cases, with BRCA1 alterations detected in six patients and BRCA2 alterations in two patients. This prevalence was statistically significantly higher than the five point eight percent frequency documented in previously published historical cohorts of breast cancer patients diagnosed below the age of forty-five years. An additional six gestational patients carried variants of uncertain significance across the two genes. These findings align with experimental models indicating that BRCA1 and BRCA2 transcript expression fluctuates alongside mammary epithelial proliferation during gestation, supporting hypotheses that hormonal and physiological stimuli during pregnancy may accelerate tumorigenesis in genetically susceptible individuals.

Evaluation of intrinsic tumor subtypes via the standardized PAM50 gene expression classifier demonstrated dramatic shifts in the molecular landscape of gestational breast cancer. Among fifty gestational tumors with successful profiling, the basal-like subtype emerged as the single most prevalent phenotype, accounting for forty-four percent of cases. By contrast, the luminal A subtype was observed in only fourteen percent of patients, while no gestational tumors were categorized as the claudin-low subtype. In the age-matched non-gestational control cohort comprising two hundred eighty-seven combined cases from the GEICAM/9906 trial and the Malaga Cohort, luminal B represented the predominant subtype at thirty-three point four percent, while basal-like tumors represented only thirteen point nine percent. Statistical testing confirmed a significant enrichment of the aggressive basal-like phenotype and a concomitant depletion of luminal A biology in gestational tumors, reinforcing the conclusion that pregnancy-associated cases disproportionately manifest adverse intrinsic subtypes independently of patient chronological age.

Assessment of stromal tumor-infiltrating lymphocytes demonstrated that gestational breast cancers operate within an altered, comparatively suppressed immune microenvironment. Quantified across hematoxylin and eosin tissue sections from fifty-five gestational tumors using standardized International Immuno-Oncology Biomarker Working Group parameters, fifty-six point four percent of specimens exhibited low lymphocytic infiltration, defined as ten percent or less stromal coverage. Intermediate infiltration occurred in twenty-five point five percent of tumors, and high infiltration was present in eighteen point two percent. When compared against an age-matched external cohort of patients aged forty years or younger where intermediate infiltration predominated at forty point three percent and low infiltration occurred in thirty-eight point three percent, gestational tumors showed a statistically significant predominance of low immune presence. Interestingly, immune infiltration varied significantly by gestational timing: patients diagnosed while actively pregnant exhibited predominantly low lymphocyte infiltration, whereas patients diagnosed during the postpartum period exhibited higher immune densities, reflecting known postpartum inflammatory involution processes.

Beyond subtype distributions and immune counts, gene expression profiling utilizing a customized Nanostring nCounter panel encompassing one hundred five breast cancer-related transcripts identified distinctive transcriptomic signatures separating gestational from non-gestational tumors across all intrinsic subtypes. Significance analysis of microarrays, unsupervised hierarchical clustering, and principal component analysis confirmed reproducible expression differences between gestational cases and matched controls within the luminal A, luminal B, HER2-enriched, and basal-like categories. Metascape and gene set enrichment analyses revealed coordinated dysregulation of pathways governing cell cycle progression, DNA damage repair, and genomic stability. In particular, the regulatory genes MYBL2 and UBE2T were consistently dysregulated in gestational malignancies across all intrinsic subtypes. Elevated expression of MYBL2 is recognized to correlate with aggressive disease progression and metastatic recurrence, while upregulation of the ubiquitin-conjugating enzyme UBE2T is implicated in cellular responses to DNA replication stress.

To explore whether global transcriptomic profiles could reliably distinguish gestational tumors from standard early-onset breast malignancies, investigators trained neural network predictive classifiers using normalized gene expression data. Across the global dataset encompassing all intrinsic subtypes, the neural network models achieved average cross-validated sensitivity and specificity values of seventy-two percent and seventy-three percent, respectively. When classifiers were constructed within individual molecular subtypes using balanced resampling matrices, the predictive accuracy remained consistent. Subtype-specific neural networks achieved sensitivity and specificity values of seventy percent and sixty-nine percent in luminal A tumors, sixty-seven percent and sixty-seven percent in luminal B tumors, sixty-eight percent and sixty-six percent in HER2-enriched tumors, and seventy percent and seventy percent in basal-like tumors, corroborating the presence of subtle, pervasive expression differences that transcend conventional subtype boundaries.

The study authors noted several methodological considerations and logistical limitations inherent to researching an uncommon condition that accounts for a small minority of total breast cancer diagnoses. The relatively small sample size of seventy gestational patients reflects recruitment hurdles associated with low overall incidence, while the necessity of including archival specimens obtained after neoadjuvant systemic therapy for nineteen patients introduced potential treatment-related expression influences. Furthermore, relying on multiple distinct historical clinical trial cohorts as comparator populations introduced minor technological heterogeneity and potential selection biases, given that certain comparator trials enrolled advanced or metastatic cases. Nevertheless, the investigators concluded that the biological distinctions observed—spanning elevated BRCA mutation rates, basal-like subtype enrichment, gestational immunosuppression, and transcriptomic shifts in DNA repair machinery—demonstrate that gestational breast cancer represents a distinctive clinicopathological entity warranting dedicated clinical investigations and tailored therapeutic strategies.

Subject of Research: Molecular, genetic, and clinico-epidemiological characterization of gestational breast cancer compared to age-matched non-gestational controls

Article Title: Gestational breast cancer: distinctive molecular and clinico-epidemiological features

Article References: de la Haba-Rodríguez, J. R., Mínguez, P., Rojo, F., Martín, M., Alba, E., Servitja, S., Prat, A., Pérez-Fidalgo, J. A., Gavilá, J., Morales, C., Rodriguez-Lescure, A., Herrero, C., Peña-Enriquez, R., Herranz, J., Hernando, C., Hernández-Blanquisett, A., Guil-Luna, S., Martinez, M., Blanch, S., … Bermejo, B. (2024). Gestational breast cancer: distinctive molecular and clinico-epidemiological features. Journal of Mammary Gland Biology and Neoplasia, 29(1), Article 18. https://doi.org/10.1007/s10911-024-09571-3

Image Credits: AI Generated

DOI: 10.1007/s10911-024-09571-3

Keywords: gestational breast cancer, GEICAM, BRCA1, BRCA2, PAM50, basal-like breast cancer, tumor infiltrating lymphocytes, Ki67, gene expression profiling, MYBL2, UBE2T, pregnancy-associated cancer, DNA repair pathways, breast cancer genomics, tumor microenvironment, postpartum breast cancer

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway